Document Detail

Major adverse noncardiac events after PCI as predictors of long-term mortality.
MedLine Citation:
PMID:  18705635     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Studies of percutaneous coronary intervention (PCI) routinely report major adverse cardiovascular events (MACE), but not major adverse noncardiac events (MANE) after PCI. MANE, such as post-PCI bleeding and contrast nephropathy, adversely influence survival, but are not recognized as a standard composite of complications. We assessed the feasibility and prognostic utility of deriving a composite of MANE. METHODS: In 985 consecutive patients who underwent PCI, we estimated the incidence and prognostic impact of in-hospital MACE (myocardial infarction [MI] target vessel revascularization, or stroke) and MANE (defined as thrombolysis in myocardial infarction [TIMI], bleeding [major or minor], or contrast nephropathy) and their impact on long-term survival. RESULTS: The incidence of MANE was >6-fold greater than MACE (9.5% vs 1.5%). Independent correlates of MANE included age, female gender, peripheral vascular disease, lower left ventricular ejection fraction, and use of an intraaortic balloon pump (IABP) during PCI. Of 973 patients who survived the index hospitalization, death occurred in 169(17%) at a median follow-up of 4.0 years. MANE (but not MACE) showed a significant relation with survival; 34 of 85 patients with MANE compared to 135 of 888 patients without MANE died during follow-up (40% vs 15%, log-rank P < 0.0001). After adjustment for several baseline clinical features, the occurrence of MANE was independently associated with a significant increase in long-term mortality (adjusted hazards ratio [HR]= 1.72, CI = 1.05-2.83) and myocardial infarction (adjusted HR = 3.43, CI = 1.55-7.58). CONCLUSIONS: After PCI, MANE are common and carry grave long-term prognostic significance. Our findings emphasize the need to monitor and report MANE, in addition to MACE, in PCI-related trials.
Kishore Harjai; Chetan Shenoy; Amol Raizada; Manivel Eswaran; Subasit Acharji; Sudhakar Sattur; Pamela Orshaw; Srinivas Devarakonda
Related Documents :
23736735 - Increasingly sensitive assays for cardiac troponins: a review.
25038045 - Hand2 elevates cardiomyocyte production during zebrafish heart development and regenera...
24879975 - Inotrope use and outcomes among patients hospitalized for heart failure: impact of syst...
18004115 - Relationship of admission haematological indices with infarct-related artery patency in...
16325285 - Prognosis of patients with atherothrombotic disease: a prospective survey in a non-hosp...
20380835 - The role of macrophage-derived urokinase plasminogen activator in myocardial infarct re...
Publication Detail:
Type:  Journal Article     Date:  2008-08-13
Journal Detail:
Title:  Journal of interventional cardiology     Volume:  21     ISSN:  1540-8183     ISO Abbreviation:  J Interv Cardiol     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-11-17     Completed Date:  2009-03-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907826     Medline TA:  J Interv Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  395-402     Citation Subset:  IM    
Guthrie Clinic, One Guthrie Square, Sayre, PA 18840, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Contrast Media / adverse effects
Coronary Angiography / adverse effects*
Follow-Up Studies
Middle Aged
Myocardial Revascularization / adverse effects*
Outcome and Process Assessment (Health Care)
Pennsylvania / epidemiology
Proportional Hazards Models
Treatment Outcome
Vascular Diseases / mortality*,  therapy*
Reg. No./Substance:
0/Contrast Media

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Performance of coronary procedures through the transulnar access without assessment of the integrity...
Next Document:  Differences in the inflammatory response between patients with and those without diabetes mellitus a...